<title>1. INTRODUCTION</title> <p>Peroxisome proliferator-activated receptor-<italic>γ</italic> (PPAR<italic>γ</italic>) as a
ligand-activated transcription factor belongs to the members of nuclear hormone
receptor superfamily. PPAR<italic>γ</italic> is implicated in a wide
variety of cellular functions, regulating the expression of gene networks required
for cell proliferation, differentiation, morphogenesis, and metabolic homeostasis. The
transforming growth factor isoforms (TGF<italic>β</italic>1, <italic>β</italic>2, and <italic>β</italic>3)
as the members of the TGF<italic>β</italic> superfamily are ubiquitously expressed 
cytokines [##REF##17729308##1##, ##REF##10593858##2##]. TGF<italic>β</italic>
exerts multiple functions with differential expression pattern in organs: each form
of TGF<italic>β</italic> has similar biological activities [##REF##1637557##3##]. Among the TGF<italic>β</italic>
forms, it is recognized that TGF<italic>β</italic>1 plays a major role in the regulation of cell proliferation and differentiation.
In this review paper, we will discuss the role of PPAR<italic>γ</italic> on TGF<italic>β</italic> gene expression.</p> <p>Accumulating evidences suggest that the interplay of PPAR<italic>γ</italic> and TGF<italic>β</italic>
contributes to the regulation of cell proliferation, differentiation, and their
associated cellular functions. For instance, the interaction of PPAR<italic>γ</italic>
signaling with the proteins affected by the activation of TGF<italic>β</italic>
receptor determines the outcome of the breast tumor progression [##REF##17367502##4##]. Many studies have shown that agonist-induced activation
of PPAR<italic>γ</italic> interferes with TGF<italic>β</italic>/Smad-dependent or Smad-independent signaling in different cell 
types [##REF##11590167##5##–##REF##14693716##12##]. The crosstalk between PPAR<italic>γ</italic>
and TGF<italic>β</italic> can be achieved not only by PPAR<italic>γ</italic>-dependent modulation of the propagation of TGF<italic>β</italic>/TGF<italic>β</italic>
receptor-mediated signaling pathways, but also by the regulation of TGF<italic>β</italic>1
expression itself and TGF<italic>β</italic>1-inducible target genes. Hence, suppression of TGF<italic>β</italic> signaling by PPAR<italic>γ</italic> could be counteracted by the inhibitory action of TGF<italic>β</italic> on the PPAR<italic>γ</italic>-mediated signaling [##REF##10625669##13##–##REF##16959952##15##].</p> <p>The TGF<italic>β</italic>1 expression is regulated at multiple levels. Diverse transcription factors are
involved in the transcriptional regulation of TGF<italic>β</italic> gene expression and post-translational modification makes precursors bound with
TGF<italic>β</italic>1 binding proteins mature to TGF<italic>β</italic> molecule [##REF##2909528##16##, ##REF##11104663##17##]. The role of PPAR<italic>γ</italic> activation in TGF<italic>β</italic>1
gene repression has been examined by the experiments using thiazolidinedione
PPAR<italic>γ</italic> agonists [##REF##16611854##18##, ##REF##12711314##19##]. These studies on the
regulation of the TGF<italic>β</italic>1 gene and the molecular interaction of ligand-activated nuclear receptors for the
activation of responsible transcription factor(s) brought insights into the
transcriptional control mechanism. The research results showed that PPAR<italic>γ</italic>
activation might transrepress the TGF<italic>β</italic> gene, interfering with TGF<italic>β</italic>
signaling and thereby altering the expression of TGF<italic>β</italic>-inducible
target genes [##REF##16611854##18##], substantiating the fact that ligand activation of PPAR<italic>γ</italic>
modulates TGF<italic>β</italic> receptor-mediated gene regulation.</p>
<p>Recommended by Dipak Panigrahy</p> <p>Peroxisome proliferator-activated receptor-<italic>γ</italic> (PPAR<italic>γ</italic>) and retinoic acid X-receptor (RXR) heterodimer, which regulates cell growth and differentiation, represses the TGF<italic>β</italic>1 gene that encodes for the protein involved in cancer biology. This review will introduce the novel mechanism associated with the inhibition of the TGF<italic>β</italic>1 gene by PPAR<italic>γ</italic> activation, which regulates the dephosphorylation of Zf9 transcription factor. Pharmacological manipulation of TGF<italic>β</italic>1 by PPAR<italic>γ</italic> activators can be applied for treating TGF<italic>β</italic>1-induced pathophysiologic disorders such as cancer metastasis and fibrosis. In this article, we will discuss the opposing effects of TGF<italic>β</italic> on tumor growth and metastasis, and address the signaling pathways regulated by PPAR<italic>γ</italic> for tumor progression and suppression.</p>
<title>2. TGF<italic>β</italic> AND CANCER CELL BIOLOGY</title> <p>TGF<italic>β</italic>1 exerts its diverse biological
effects by acting on distinct combinations of type I and type II receptors and
recruiting downstream signal transducers including Smads, consequently
regulating a group of target gene expression responsible for a specific
biological activity. Smad proteins are
classified into R-Smads (receptor-regulated Smads: Smads 1, 2, 3, 5, and 8), Co-Smads
(common mediator Smad: Smad 4), and I-Smads (inhibitory Smads: Smad 6 and 7), and
these play roles as the transcriptional regulators for the superfamily of TGF<italic>β</italic>1-inducible
target genes [##REF##17729308##1##, ##REF##10593858##2##, ##REF##11278686##20##–##REF##10733523##22##]. Smad 2 and Smad 3 are the specific mediators of TGF<italic>β</italic>1, whereas Smad 1, Smad 5, and MADH6/Smad 9 are crucial
for bone morphogenic protein signaling [##REF##10733523##22##]. In particular, Smad 3 is involved in
the TGF<italic>β</italic>1 gene regulation, which
is crucial for the autocrine function of TGF<italic>β</italic>1 [##REF##11262418##23##].</p> <p>Following the activation of the TGF<italic>β</italic>1 receptor by TGF<italic>β</italic>1, TGF<italic>β</italic>1-induced receptor kinase activation rapidly
phosphorylates Smads proteins and initiates formation of functional oligomeric
complexes. The resultant oligomeric complex translocates to the nucleus to
regulate target gene expression. Briefly, the type I TGF<italic>β</italic>1 receptor kinase phosphorylates serine residues at the
C-terminal SSXS motif in the MH2 domain of Smad 3 (or Smad 2) [##REF##10660041##24##]. Phosphorylated 
Smad 3 (or Smad 2) forms an
oligomeric complex with Smad 4, which is crucial for the maximal transcription
of diverse TGF<italic>β</italic>1-inducible target genes [##REF##9843964##25##, ##REF##11013220##26##]. The oligomeric complexes
of Smad 3 (or Smad 2) and Smad 4 recognize DNA binding element tetranucleotide
(CAGA) or GC-rich sequences, and several copies of which are present in the
promoter regions of many TGF<italic>β</italic>1-responsive genes such
as plasminogen activator inhibitor-1 (PAI-1), <italic>α</italic>2(I) procollagen, and type VII collagen [##REF##9843964##25##, ##REF##9606191##27##]. It is
well known that the protein products encoded from these genes promote the accumulation
of extracellular matrix and that abnormal accumulation of the proteins may lead
to fibrosis, which represents a form of the epithelial to mesenchymal transition (EMT).</p> <p>Moreover, TGF<italic>β</italic>1-activated kinase-1, a member of MAPK kinase kinase
family, activates its MAP kinase pathways [##REF##9044838##28##, ##REF##11278290##29##]. It is accepted that TGF<italic>β</italic>1-activated ERK pathway synergistically enhances Smad
signaling of the TGF<italic>β</italic>1 receptor due to the positive cross talk between the ERK
and Smad pathways [##REF##10733523##22##, ##REF##12824291##30##]. Serine phosphorylation of Smad 3/2, but not
phosphorylation of the C-terminal motif, was decreased by MEK-ERK inhibitors [##REF##14512875##31##].
Smad 3/2 are differentially activated by TGF<italic>β</italic>1 in hepatic stellate cells as a result of the differential
phosphorylations of the Smads. Smad 3 plays a key role in TGF<italic>β</italic> signaling, which is strengthened by the observation that
the loss of Smad 3 interfered with TGF<italic>β</italic>1-mediated
induction of target genes [##REF##15987742##32##, ##REF##16341574##33##]. In addition, activation
of CCAAT/enhancer binding protein (C/EBP) <italic>β</italic> is also involved in
the inhibition of TGF<italic>β</italic>1 expression [##REF##12397085##34##].</p> <p>During the process of carcinogenesis, TGF<italic>β</italic>
action can be either tumor suppressive or tumor promoting, depending on the stage
of tumor development [##REF##15701890##35##–##REF##17898532##37##]. In an experimental
cell model, TGF<italic>β</italic> could induce cell growth arrest and promote apoptosis of
carcinoma cells [##REF##17729308##1##]. The antiproliferative action of TGF<italic>β</italic> in epithelial cells, for example, is essentially
attributed to the cell cycle arrest and the apoptosis concomitantly induced. It
is well known that cell cycle arrest induced by TGF<italic>β</italic> occurs at G1 phase through enhancing transcription of cyclin-dependent
kinase inhibitors, p21<sup>Cip1/WAF</sup> and p15<sup>Ink4b</sup>, while suppressing
the induction of c-Myc, a progrowth transcription factor, and of Id<sub>1–3</sub>,
the inhibitors of differentiation [##REF##8078588##38##–##REF##14557817##43##]. In a model of gastric adenocarinoma,
TGF<italic>β</italic>-mediated apoptosis contributed to tumor suppression,
which resulted from TGF<italic>β</italic>-induced caspase-8 activation [##REF##14595120##44##]. Moreover, it has been
shown that TGF<italic>β</italic> reduced the expression of antiapoptotic Bcl-2 family
members in prostate cancer cells [##REF##11320089##45##].</p> <p>By contrast, TGF<italic>β</italic> may also lead to tumor cell proliferation as a
consequence of EMT process [##REF##11371340##46##–##REF##17680632##48##], which is a cellular phenomenon
characterized by a loss of polarized epithelial phenotype with transition to a
mesenchymal or more migratory phenotype. Studies have shown that diverse
signaling pathways are involved in the TGF<italic>β</italic>-dependent EMT process. Initiation of EMT by TGF<italic>β</italic> receptor activation is mediated by either Smad-dependent
or Smad-independent pathway [##REF##17729308##1##, ##REF##17724470##49##, ##REF##16904831##50##]. Downstream of the TGF<italic>β</italic> receptor
activation, the Smads activated by the TGF<italic>β</italic> receptor kinase promote transcription
of the genes, which eventually play crucial roles in the process of EMT. The
responsible transcription factors primarily include Snail, Slug, and LEF-1 [##REF##17729308##1##].
In addition, TGF<italic>β</italic> also activates the non-Smad pathways, which include Ras,
phosphatidylinositol 3-kinase (PI3K), and Par 6. These molecules regulate the
expression of Snail and the activities of glycogen synthase kinase 3<italic>β</italic> (GSK3<italic>β</italic>) and RhoA, respectively [##REF##16467384##51##, ##REF##12000787##52##], thereby enhancing the process
of EMT. It is now accepted that the EMT phenomenon of primary cancer cells promoted
by the action of TGF<italic>β</italic> may increase cancer metastasis.</p> <p>TGF<italic>β</italic> acts on tumor cells directly, playing a role in cancer cell
migration and invasion. Diverse TGF<italic>β</italic>-mediated signaling pathways are responsible for this
process. In glioblastoma cells, siRNA knockdowns of TGF<italic>β</italic>1 and TGF<italic>β</italic>2 resulted in the inhibition of cell motility or invasiveness
[##REF##15492287##53##]. As a same token, TGF<italic>β</italic> released from tumor tissues
might facilitate glioma cell migration and invasion via an autocrine signaling [##REF##17541035##54##]. Several lines of evidence also support the
concept that TGF<italic>β</italic>-induced
Smad signaling is responsible for the invasiveness of cancer cells [##REF##16407850##55##–##REF##16172383##58##]. This is explained in part by the TGF<italic>β</italic>-dependent induction of matrix metalloproteases, which are known to be responsible for cell migration and
invasion [##REF##16407850##55##, ##REF##11716069##59##–##REF##11592306##62##]. Activation of ERK
and JNK by TGF<italic>β</italic> and their association with focal complexes may
also contribute to cell migration, as shown in the case of breast carcinoma [##REF##17587818##63##]. Moreover, it has been shown that the activation of p38 MAPK pathway by
TGF<italic>β</italic> facilitated invasion of head and neck squamous epithelial cells [##REF##10633074##61##].</p> <p>In addition to the double-edged effects of TGF<italic>β</italic> on cancer cells, TGF<italic>β</italic> may
alter cancer growth by suppressing the growth of multiple immune cells, which compromises
the overall immune functions. Studies have shown that the proliferation and activity
of T cells are suppressed by the TGF<italic>β</italic> blockade of IL-2 production and expression of T cell effector molecules [##UREF##1##64##–##UREF##3##68##].
Also, TGF<italic>β</italic> attenuates the activity of natural killer (NK) cells by inhibiting NK
production of interferon-<italic>γ</italic> (IFN-<italic>γ</italic>) [##UREF##4##69##, ##UREF##5##70##].
Another study showed that TGF<italic>β</italic> inhibited
the antigen presentation function of dendritic cells through suppressing the expression
of MHC class II and costimulatory molecules [##UREF##6##71##]. All of these results support
the alterations by TGF<italic>β</italic> in immune
functions, which would impair immune surveillance or attack against cancer
cells.</p> <p>In summary, action of TGF<italic>β</italic>1 on cancer cells switches from tumor suppression to tumor promotion, depending on the stage of tumor
progression. For instance, during the early phase of breast tumorigenesis, the
TGF<italic>β</italic> signal inhibits primary tumor growth
via cell growth arresting and promoting apoptosis.
However, at later stage, cancer cells acquire a capacity to escape from the
tumor suppressive effects of TGF<italic>β</italic>1 via induction of EMT. Interestingly, the aforementioned conflicting functions
of TGF<italic>β</italic> might go through the same TGF<italic>β</italic> receptor
complex and the associated signaling pathways involving Smad transcription
factors [##REF##17729308##1##]. Probably, there should be certain stage-dependent
modifications in cellular signaling system including changes in receptor
function and downstream Smad signaling cascades.
Taken together, it is concluded that TGF<italic>β</italic> may not
only induce growth arrest of cancer cells, but also increase cancer dissemination
[##REF##17729308##1##], supporting the concept that the cytokine serves a dual function in tumor development
and progression (##FIG##0##Figure 1##).</p> <title>3. PPAR<italic>γ</italic> AND CANCER BIOLOGY</title> <p>PPAR<italic>γ</italic> has been extensively studied as an anticancer target in preclinical and
clinical settings [##REF##15231248##72##]. The anticancer effects appeared to be cancer cell-specific.
A knock-out or loss of function mutation in PPAR<italic>γ</italic> can
be an important risk factor for the incidence of cancer [##REF##12370429##73##–##REF##10394368##75##]. In this sense,
PPAR<italic>γ</italic> has been considered as a novel target for designing new anticancer drugs for
chemotherapy. This is further supported by the finding that PPAR<italic>γ</italic> activators
exert a potent tumor-suppressing activity against various human cancer cells [##REF##9699665##76##–##REF##9797355##78##]. As a matter of fact, PPAR<italic>γ</italic>
activators such as troglitazone and ciglitazone exert antiproliferative
activities in epithelial cancer cell lines or animal models, which presumably
results from the activation of PPAR<italic>γ</italic> receptor and the PPAR<italic>γ</italic>
receptor-dependent pathways [##REF##9699665##76##, ##REF##14634802##79##–##REF##12727930##83##]. Nevertheless, other anticancer pathways
have also been recognized in association with PPAR<italic>γ</italic>, which might be PPAR<italic>γ</italic>
receptor-independent [##REF##10227562##84##, ##REF##16728570##85##]. Multiple PPAR<italic>γ</italic>-independent
anticancer targets of PPAR<italic>γ</italic>
agonists have been suggested in several cancer cell types. The mechanisms may comprise
a variety of pathways such as the blockade of G1-S phase transition
by inhibiting translation initiation [##REF##11507074##86##], activation of
JNK-dependent cell death pathway [##REF##12527812##87##], induction of the early growth
response-1 (Egr-1) gene [##REF##12475986##88##], inhibition of Bcl-xL and Bcl-2
function [##REF##16728570##85##], counteracting TGF<italic>β</italic>
release by tumor cells [##REF##17541035##54##], and induction
of cyclin-dependent kinase inhibitor
p21<sup>WAF1/CIP1</sup> [##REF##10441511##89##]. However, the precise antiproliferative
mechanisms of the PPAR<italic>γ</italic> agonists remain to be further studied. On the contrary, there are also other reports
available on the opposite effects showing that PPAR<italic>γ</italic> signaling promoted 
carcinogenesis [##UREF##8##90##, ##REF##15037548##91##].</p> <p>It should be noted that the antitumor effects of PPAR<italic>γ</italic> may be explained at least in two different ways. One mechanism involves cell growth
regulation [##REF##17367502##4##], which should be further clarified, whereas the other mechanism includes
cancer chemopreventive effects mediated by the induction of antioxidant enzymes
[##REF##15150131##92##]. It is well recognized that PPAR<italic>γ</italic>
affects cell survival, growth, and differentiation by acting on the peroxisomal
proliferator-response element (PPRE), thereby modulating an expression of a
group of genes controlling cell growth and differentiation pathways [##REF##17579114##93##, ##REF##17978568##94##]. The
PPAR<italic>γ</italic> homodimer and PPAR<italic>γ</italic>-retinoic acid X receptor (RXR) <italic>α</italic> heterodimer have the specificities of DNA-binding
with preferential binding of the latter to DR1, which is a PPRE DNA binding site. SRC-1 is a coactivator of
PPAR<italic>γ</italic> [##REF##10944516##95##].
Binding of the ligand-activated PPAR<italic>γ</italic>-RXR<italic>α</italic> heterodimer to its DNA binding
sites stimulates the interaction between PPAR<italic>γ</italic>-RXR<italic>α</italic> and p160/SRC-1 [##REF##10944516##95##].</p> <p>A number of studies support the concept that cancer chemoprevention is accomplished by
the induction of antioxidant enzymes. The results from our laboratories indicated
that oltipraz and flavonoids as potential cancer chemopreventive agents
activate C/EBP<italic>β</italic> in the antioxidant genes such as <italic>glutathione S-transferase (GST) A2</italic> [##REF##12509401##96##, ##REF##12663507##97##]. In addition, treatments of cells with PPAR<italic>γ</italic> activators
induced the nuclear translocation of NF-E2-related factor 2 (Nrf2) and C/EBP<italic>β</italic>, and activating Nrf2 and C/EBP<italic>β</italic> bindings to the antioxidant
response element (ARE) and C/EBP response elements, respectively [##REF##15150131##92##].
Moreover, the Nrf2 and C/EBP<italic>β</italic> genes contain PPRE sites,
which account for the induction of the target antioxidant proteins by PPAR<italic>γ</italic> activators. Both
the ARE and the C/EBP binding site have crucial roles in transactivating the GSTA2 gene by PPAR<italic>γ</italic> and RXR ligands [##REF##15150131##92##].
Therefore, Nrf2 and/or C/EBP<italic>β</italic> inductions(s) via the PPAR<italic>γ</italic> and RXR<italic>α</italic> heterodimer binding to the
PPREs in the promoter regions of the target genes contribute(s) to the antioxidant
capacity of cells (e.g., GSTA2).</p> <p>A result of our
previous study indicated that specific mutations of these nuclear binding sites in the GSTA2 promoter, which are present as a
three-PPRE cluster, caused the complete loss of its responsiveness to PPAR<italic>γ</italic> activators [##REF##15150131##92##]. All of the putative PPRE sites
comprising DR1 were functionally active. Therefore, the binding of the
activating PPAR<italic>γ</italic>-RXR
heterodimer to all of the PPRE sites appeared to be crucial for the inducible
gene activation, showing that the PPAR binding site cluster is the functionally
active PPRE-responsive enhancer module (PPREM) [##REF##15150131##92##].
This study on the regulation of gene expression by the PPAR<italic>γ</italic>-RXR
heterodimer at the promoter containing multiple DR1 elements brought additional
insight into the transcriptional control mechanism of the antioxidant enzymes.
The identified molecular mechanism would shed light on the contribution of cell
viability and cancer chemoprevention as a consequence of the induction of antioxidant 
targets genes by PPAR<italic>γ</italic> activators.</p> <title>4. TGF<italic>β</italic> REGULATION BY PPAR<italic>γ</italic>-RXR AND CELL SIGNALING</title> <p>Activation of the PPAR<italic>γ</italic>-RXR heterodimer represses the TGF<italic>β</italic>1 gene through
dephosphorylation of a transcription factor called zinc finger transcription
factor-9 (Zf9), which has been shown to be induced by phosphatase and tensin homolog deleted on chromosome (PTEN)-mediated p70 ribosomal S6 kinase-1 (S6K1) inhibition [##REF##16611854##18##]. Because RXRs
are modular proteins with a highly conserved central DNA binding domain and a
less conserved ligand binding domain [##REF##9826495##98##], activation of the PPAR<italic>γ</italic> and RXR heterodimer
contributes to the gene regulation. The role of PPAR<italic>γ</italic> in repression of the TGF<italic>β</italic>1 gene
was further evidenced by the effects of thiazolidinediones, and also by the
reversal of TGF<italic>β</italic>1 repression by the dominant negative mutants, supporting to the novel aspect
that PPAR<italic>γ</italic> activation contributes to TGF<italic>β</italic>1 gene repression
and that RXR<italic>α</italic> is necessary for the full responsiveness in the gene repression. In
fact, the inhibition of TGF<italic>β</italic>1 gene by the PPAR<italic>γ</italic>
and RXR heterodimer might account for either tumor suppression or tumor
promotion [##REF##16611854##18##]. Also, as an effort to identify the molecular
basis of TGF<italic>β</italic>1 repression by PPAR<italic>γ</italic> activators, the effects of PPAR<italic>γ</italic> and RXR activation on 
the TGF<italic>β</italic>1 gene transactivation, that is regulated by the proximal DNA response elements, have
been examined [##REF##16611854##18##]. The potential regulatory sites responsible for the TGF<italic>β</italic>1 gene expression have been explored by
using the luciferase reporter gene assays, which identified the putative PPREs
located at the multiple sites upstream from −453 bp of the
promoter region [##REF##16611854##18##]. Promoter deletion analyses indicate that neither the
putative PPREs nor the activator protein-1 (AP-1) binding sites are directly
regulated by PPAR<italic>γ</italic> activators forthe gene repression.</p> <p>S6K1, a ubiquitous serine/threonine kinase, controls the translational efficiency by phosphorylating
ribosomal S6 protein [##REF##3257566##99##].
S6K1 functions as a multifunctional kinase for
the phosphorylation of ribosomal S6 protein [##REF##3257566##99##], CREM [##REF##7923380##100##], BAD [##REF##11493700##101##], and the eukaryotic
elongation factor 2 kinase [##REF##11500364##102##]. Rapamycin, a well-known mammalian target of
rapamycin (mTOR) inhibitor, inhibited liver fibrosis and TGF<italic>β</italic>1 expression in rats bile duct-ligated or
challenged with toxicants [##REF##10535884##103##, ##REF##15769867##104##], with a concomitant decrease in S6K1
activity. It is well recognized that rapamycin
inhibits S6K1 activity via mTOR inhibition [##REF##7518356##105##]. Yet, other pharmacological agents that modulate S6K1
activity have not been reported. The mechanism of PPAR<italic>γ</italic>-RXR
heterodimer-mediated repression of the TGF<italic>β</italic>1 gene has been
elucidated in terms of the modulation of S6K1 activity (##FIG##1##Figure 2##).</p> <p>The PI3K-mTOR pathway regulates S6K1 for the regulation of transcription factors
involved in the TGF<italic>β</italic>1 gene transactivation. A study identified the
inhibition of S6K1 activity by the PPAR<italic>γ</italic>-RXR, which contributes to TGF<italic>β</italic>1 gene 
repression [##REF##16611854##18##].
Another signaling molecule, PTEN, antagonizes the PI3-kinase-mTOR-S6K1-mediated signaling
cascade [##REF##15788448##106##, ##REF##15988030##107##]. Thus, it has been elucidated that PPAR<italic>γ</italic> activators
upregulate PTEN, which leads to the S6K1 inhibition, consequently causing TGF<italic>β</italic>1 
repression [##REF##16611854##18##].</p> <title>5. TRANSCRIPTION FACTORS RESPONSIBLE FOR TGF<italic>β</italic> REPRESSION BY PPAR<italic>γ</italic>-RXR</title> <p>In the promoter region of the TGF<italic>β</italic>1 gene
(##FIG##2##Figure 3##), the putative binding sites for PPAR<italic>γ</italic>-RXR seemed to be neither active nor
responsible for the gene repression by the activated PPAR<italic>γ</italic> and RXR heterodimer.
It has been claimed that the effects of PPAR<italic>γ</italic> or retinoid ligands on TGF<italic>β</italic>1 gene 
expression might be mediated in part by AP-1 inhibition [##REF##12711314##108##, ##REF##8264664##109##]. Nevertheless, such a
result that deletion of the DNA region containing both AP-1 sites still had the
capability to repress the gene by PPAR<italic>γ</italic> activator suggests that the AP-1
binding sites might not be a major regulatory target in the TGF<italic>β</italic>1 gene
repression. Rather, the target molecule altered by PPAR<italic>γ</italic>-RXR<italic>α</italic>-activated cell signal may be
involved in the interaction with the protein recruited on the AP-1 DNA complex.
It appeared that the TGF<italic>β</italic>1 gene
repression may have not resulted from the direct inhibition of AP-1, but other
mechanistic basis [##REF##16611854##18##].</p> <p>Another study showed that the mechanism associated with the inhibition of TGF<italic>β</italic>1 
by PPAR<italic>γ</italic> activators involves the regulation of c-Fos [##REF##12711314##108##]. In the study, thiazolidinediones inhibit
high-glucose-induced TGF<italic>β</italic>1 promoter activity. A suggested mechanism was raised based on the observation that treatments of thiazolidinediones
reduced high-glucose-induced, activated PKC and c-Fos-mediated TGF<italic>β</italic>1 gene expression in mesangial
cells [##REF##12711314##108##].</p> <p>Zf9 as an immediate early gene reduces cell
proliferation with the induction of p21<sup>cip1</sup> and the enhancement of
c-Jun degradation [##REF##11752579##110##, ##REF##15378003##111##], thus functioning as a potential tumor suppressor
gene. The transcription factors that interact
with the known DNA binding sites on the region downstream within the −323 bp of the TGF<italic>β</italic>1 gene include Zf9, NF1, and SP1. It is noteworthy that Zf9 activation
induces TGF<italic>β</italic>1 during the activation of hepatic
stellate cells [##REF##9689109##112##]. Also, Zf9 regulates TGF<italic>β</italic> receptors and collagen <italic>α</italic>1(I), promoting accumulation of extracellular
matrix [##REF##9837963##113##]. Studies have shown that Zf9
phosphorylation enhances its nuclear localization and transcriptional activity [##REF##15378003##111##].
Zf9 as a transcription factor plays a crucial role for the induction of TGF<italic>β</italic>1 [##REF##9837963##113##]. Thus, phosphorylation status of Zf9 may contribute
to the promotion of its target gene expression
[##REF##12590140##114##]. Identification
of the partners of Zf9 or phosphorylated Zf9 for the TGF<italic>β</italic>1 gene
regulation and their molecular interactions would be interesting to pursue. The constitutive Zf9 phosphorylation by S6K1 strengthened the important role of S6K1
as a multifunctional kinase for the transcription
factor regulation of target genes [##REF##7923380##100##–##REF##11500364##102##].</p> <p>The TGF<italic>β</italic>1 gene contains the DNA
response element interacting with Zf9 [##REF##2909528##16##] that regulates multiple genes
involved in tissue differentiation. Activation of Zf9 includes its
phosphorylation at serine (or tyrosine) residues [##REF##12590140##114##]. Thus, phosphorylation
of Zf9 leads to transcription of its target genes [##REF##15378003##111##, ##REF##12590140##114##]. Although the
kinase catalyzing Zf9 phosphorylation has not been completely identified, the
inhibition of Zf9 phosphorylation by rapamycin that inhibits S6K1 activity via
mTOR inhibition supports the role of S6K1 in Zf9 phosphorylation [##REF##16611854##18##]. More
importantly, the role of S6K1 in regulating TGF<italic>β</italic>1 gene and the associated molecular mechanistic basis have
been clarified in terms of Zf9 dephosphorylation [##REF##16611854##18##]. In view of the previous
observations that Zf9 is crucial as a transcription factor for TGF<italic>β</italic>1 induction in hepatic stellate cells [##REF##9837963##113##] and
that a phosphorylated form of Zf9 plays a role in the transactivation of the
target gene promoter [##REF##12590140##114##], the potential ability of PPAR<italic>γ</italic> activators to inhibit serine phosphorylation
of the transcription factor has also been investigated. Thus, it has been demonstrated
that the inhibition of the TGF<italic>β</italic>1 gene by the activation of PPAR<italic>γ</italic>-RXR includes Zf9
dephosphorylation [##REF##16611854##18##]. Therefore, TGF<italic>β</italic>1 gene repression by PPAR<italic>γ</italic> activators appears to be related with
dephosphorylation of Zf9, supporting the conclusion
that the PPAR<italic>γ</italic>-RXR heterodimer causes TGF<italic>β</italic>1 repression via S6K1 inhibition, 
and that the inhibition of S6K1 activity provides a central mechanism, by which PPAR<italic>γ</italic>-RXR regulates 
Zf9-dependent TGF<italic>β</italic>1 gene expression (##FIG##1##Figure 2##).</p> <p>Moreover, it has been shown that PPAR<italic>γ</italic> activation induces PTEN, which serves as a 
PI(3,4,5)P<sub>3</sub> lipid phosphatase and antagonizes
PI3-kinase-mediated cell signaling [##REF##15788448##106##]. Functional PPREs located in the PTEN
promoter have been recognized [##REF##11378386##115##]. The induction of PTEN by PPAR<italic>γ</italic> activators may result
in TGF<italic>β</italic>1 gene repression following S6K1 inhibition. Furthermore, PPAR<italic>γ</italic>
activators inhibited phosphorylations of Akt, ERK1/2, p90 ribosomal S6 kinase-1
(RSK1), and mTOR, downstream of PTEN, indicating that PTEN induction by PPAR<italic>γ</italic>
activators leads to S6K1 inhibition via the pathways of ERK1/2-RSK1 as well as
Akt-mTOR. In conclusion, the result showing that PPAR<italic>γ</italic> activation upregulates PTEN,
which has also been implicated in tumor-inhibitory or anti-inflammatory actions
of PPAR<italic>γ</italic> [##REF##15788448##106##, ##REF##11378386##115##], gives credence to
the concept that PPAR<italic>γ</italic> activators induce PTEN during
S6K1 inhibition, and consequently causes TGF<italic>β</italic>1 repression. Therefore, the inhibition of tumor proliferation by PPAR<italic>γ</italic>
activators may be explained in part by PPAR<italic>γ</italic>-dependent TGF<italic>β</italic>1 repression 
(##FIG##1##Figure 2##), supporting the concept that the PPAR<italic>γ</italic> activators may be applied for
controlling TGF<italic>β</italic>1-induced cancer metastasis and fibrosis.</p>
<title>ACKNOWLEDGMENT</title> <p>This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Ministry of Science and Technology
(MOST), South Korean government (no.R11-2007-107-01001-0).</p>
<fig id="fig1" position="float"><label>Figure 1</label><caption><p>A scheme showing the opposing effects of TGF<italic>β</italic> on tumor growth and metastasis.</p></caption></fig> <fig id="fig2" position="float"><label>Figure 2</label><caption><p>A schematic presentation of the multiple pathways regulated by PPAR<italic>γ</italic> for
tumor suppression, progression, inhibition of metastasis, and cancer
chemoprevention.</p></caption></fig> <fig id="fig3" position="float"><label>Figure 3</label><caption><p>The human TGF<italic>β</italic>1 promoter region.</p></caption></fig>
<graphic xlink:href="PPAR2008-762398.001"/> <graphic xlink:href="PPAR2008-762398.002"/> <graphic xlink:href="PPAR2008-762398.003"/>
[{"label": ["6"], "surname": ["Wang", "Liu", "Chen"], "given-names": ["W", "F", "N"], "article-title": ["Peroxisome proliferator-activated receptor-"], "italic": ["\u03b3", "\u03b3", "\u03b2", "Mediators of Inflammation"], "year": ["2007"], "volume": ["2007"], "comment": ["Article ID 62641, 7 pages."]}, {"label": ["64"], "surname": ["Li", "Wan", "Sanjabi", "Robertson", "Flavell"], "given-names": ["MO", "YY", "S", "A-KL", "RA"], "article-title": ["Transforming growth factor-"], "italic": ["\u03b2", "Annual Review of Immunology"], "year": ["2006"], "volume": ["24"], "fpage": ["99"], "lpage": ["146"]}, {"label": ["66"], "surname": ["Ma", "Koka", "Burkett"], "given-names": ["A", "R", "P"], "article-title": ["Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis"], "italic": ["Annual Review of Immunology"], "year": ["2006"], "volume": ["24"], "fpage": ["657"], "lpage": ["679"]}, {"label": ["68"], "surname": ["Ahmadzadeh", "Rosenberg"], "given-names": ["M", "SA"], "article-title": ["TGF-"], "italic": ["\u03b2", "Journal of Immunology"], "year": ["2005"], "volume": ["174"], "issue": ["9"], "fpage": ["5215"], "lpage": ["5223"]}, {"label": ["69"], "surname": ["Rook", "Kehrl", "Wakefield"], "given-names": ["AH", "JH", "LM"], "article-title": ["Effects of transforming growth factor "], "italic": ["\u03b2", "Journal of Immunology"], "year": ["1986"], "volume": ["136"], "issue": ["10"], "fpage": ["3916"], "lpage": ["3920"]}, {"label": ["70"], "surname": ["Bellone", "Aste-Amezaga", "Trinchieri", "Rodeck"], "given-names": ["G", "M", "G", "U"], "article-title": ["Regulation of NK cell functions by TGF-"], "italic": ["\u03b2", "Journal of Immunology"], "year": ["1995"], "volume": ["155"], "issue": ["3"], "fpage": ["1066"], "lpage": ["1073"]}, {"label": ["71"], "surname": ["Geissmann", "Revy", "Regnault"], "given-names": ["F", "P", "A"], "article-title": ["TGF-"], "italic": ["\u03b2", "Journal of Immunology"], "year": ["1999"], "volume": ["162"], "issue": ["8"], "fpage": ["4567"], "lpage": ["4575"]}, {"label": ["81"], "surname": ["Sarraf", "Mueller", "Jones"], "given-names": ["P", "E", "D"], "article-title": ["Differentiation and reversal of malignant changes in colon cancer through PPAR"], "italic": ["\u03b3", "Nature Medicine"], "year": ["1998"], "volume": ["4"], "issue": ["9"], "fpage": ["1046"], "lpage": ["1052"]}, {"label": ["90"], "surname": ["Lefebvre", "Chen", "Desreumaux"], "given-names": ["A-M", "I", "P"], "article-title": ["Activation of the peroxisome proliferator-activated receptor "], "italic": ["\u03b3", "M", "i", "n", "Nature Medicine"], "year": ["1998"], "volume": ["4"], "issue": ["9"], "fpage": ["1053"], "lpage": ["1057"]}]
PPAR Res. 2008 Jul 3; 2008:762398